RCEL

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

9.540

Open

9.210

VWAP

9.34

Vol

136.80K

Mkt Cap

250.20M

Low

8.830

Amount

1.28M

EV/EBITDA(TTM)

Total Shares

25.80M

249.82M

EV/OCF(TTM)

P/S(TTM)

3.71

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

20.99M

+89.02%

-0.326

-55.39%

23.66M

+55.33%

-0.243

-59.6%

27.82M

+42.15%

-0.120

-80.7%

Estimates Revision

The market is revising Downward the revenue expectations for AVITA Medical, Inc. (RCEL) for FY2025, with the revenue forecasts being adjusted by -6.14% over the past three months. During the same period, the stock price has changed by 9.04%.

Revenue Estimates for FY2025

Revise Downward

-6.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+245.07%

In Past 3 Month

Stock Price

Go Up

+9.04%

In Past 3 Month

6 Analyst Rating

71.16% Upside

Wall Street analysts forecast RCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is 16.20 USD with a low forecast of 11.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

2 Hold

0 Sell

Moderate Buy

71.16% Upside

Current: 9.465

Low

11.00

Averages

16.20

High

22.00

71.16% Upside

Current: 9.465

Low

11.00

Averages

16.20

High

22.00

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$22

2025-04-10

Reason

D. Boral Capital

Jason Kolbert

Price Target

$22

2025-04-10

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$22

2025-04-04

Reason

D. Boral Capital

Jason Kolbert

Price Target

$22

2025-04-04

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$22

2025-03-18

Reason

D. Boral Capital

Jason Kolbert

Price Target

$22

2025-03-18

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$25 → $22

2025-02-20

Reason

D. Boral Capital

Jason Kolbert

Price Target

$25 → $22

2025-02-20

Maintains

Strong Buy

Reason

D. Boral Capital lowered the firm's price target on Avita Medical to $22 from $25 and keeps a Buy rating on the shares. The CFO of Avita informed D. Boral that the company has no plans to enter the chronic wounds market for the foreseeable future. As a result, the firm removed chronic wounds from its model and adjusted its acute wounds market share assumptions to align with the company's published guidance. With limited resources, Avita is prioritizing areas where its product attributes can have the greatest impact, the analyst tells investors in a research note.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$25

2025-02-14

Reason

D. Boral Capital

Jason Kolbert

Price Target

$25

2025-02-14

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$25

2025-01-08

Reason

D. Boral Capital

Jason Kolbert

Price Target

$25

2025-01-08

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for AVITA Medical Inc (RCEL.O) is -13.00, compared to its 5-year average forward P/E of -6.25. For a more detailed relative valuation and DCF analysis to assess AVITA Medical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.25

Current PE

-13.00

Overvalued PE

8.97

Undervalued PE

-21.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

13.42

Current EV/EBITDA

-14.20

Overvalued EV/EBITDA

105.14

Undervalued EV/EBITDA

-78.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

8.83

Current PS

2.32

Overvalued PS

15.86

Undervalued PS

1.79